Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, give an overview of chronic lymphocytic leukemia, the standard of care for treatment, and the current and emerging BTK inhibitors used to treat CLL.
Back
Updates in CLL: A Closer Look at Adverse Events
Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, discuss adverse events associated with treating chronic lymphocytic leukemia, particularly when utilizing BTK inhibitors.
Updates in CLL: A Closer Look at Adverse Events
Episodes
All
All
Two experts discuss key safety considerations when treating patients with chronic lymphocytic leukemia.
Drs Lenneman and Awan discuss baseline testing before choosing a treatment strategy for battling chronic lymphocytic leukemia.
Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, review the risk versus benefit of anticoagulation strategies in patients on BTKi.
Two experts discuss strategies for managing atrial fibrillation in patients with CLL on BTKi therapy.
Farrukh Awan shares a case of a patient with a cardiac history recently diagnosed with CLL requiring treatment.
Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, review strategies for managing hypertension in patients with CLL.
Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, close out the program answering audience questions regarding potential adverse events surrounding the utilization of BTK inhibitors in the management of chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5